Mission News Management Advisory Board


MolecularWare, Inc. Appoints Senior Advisory Board

CAMBRIDGE, Mass., May 2002 - MolecularWare, Inc. today announced its senior advisory board, a seasoned group of biotech industry executives and financiers. The group includes past and present leaders of companies such as Cortek, Wildfire Communications, Oxford Molecular Group (now part of Pharmacopeia), and RA Capital Asosciates, as well as faculty at the Harvard Business School and the Massachusetts Institute of Technology.

"We are thrilled to have the expertise and experience of this group guiding us as we move past start-up mode to become an industry contender in the bioinformatics space," said MolecularWare CEO Richard P. Kivel. "The combination of their business acumen and technical depth will ensure our success for years to come."

Advisory members are:

Richard H. Aldrich, Founding Partner of RA Capital Associates and past Senior Vice President and Chief Business Officer at Vertex Pharmaceuticals.

Joseph B. Lassiter III, Ph.D, Professor of Management Practice at the Harvard Business School and former President of Wildfire Communications.

James E. Nicholson, CEO of Cortek, Inc. and Founder of Mitek Surgical and Innovasive Devices, Inc.

Charles A. Nalbantian, health sciences business consultant and former CEO of Oxford Molecular Group, Inc. (a unit within Pharmacopeia Inc.ís software subsidiary Accelrys Inc.).

Anthony J. Sinskey, Sc.D., Professor of Microbiology at the MIT Department of Biology and member of the Malaysia-MIT Biotechnology Partnership Program.

Eric S. Silverman, Founding Partner of Co-Capital in Wellesley, Mass., and past President of Aspen Investment Group.

MolecularWare, founded in 1998, provides scientists with software to rapidly store, annotate, and search information derived from high-throughput biology research. Its DigitalGenomeTM product is used in commercial and academic facilities around the world.

For more information, please contact:
Anne McCrory, Media Relations
MolecularWare, Inc.
Richard P. Kivel, CEO
MolecularWare Inc.